NCT05626634 2025-12-03Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyLongboard PharmaceuticalsPhase 2 Completed41 enrolled
NCT04737174 2022-04-06ES-481 for Uncontrolled Glioma-Associated Epilepsy and Assessment for Potential Anti-Tumorigenic Effect in Patients With Isocitrate Dehydrogenase 1 (IDH1) Mutant TumorsES Therapeutics Australia Pty LtdPhase 2 Withdrawn